Johns Hopkins ABX Guide
Dolutegravir
To view the entire topic, please log in or purchase a subscription.
Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:
-- The first section of this topic is shown below --
INDICATIONS
FDA
Tivicay: Treatment of HIV-1 infection in combination with other ARV agents in adults and children weighing ≥30 kg
Triumeq: Treatment of HIV-1 infection in adults and children weighing ≥40 kg
Juluca: Treatment of HIV-1 infection as a complete regimen for adult patients already virologically suppressed on stable ART for 6 months and no known resistance to dolutegravir or rilpivirine
NON-FDA APPROVED USES
Non-occupational post-exposure prophylaxis (nPEP) in combination with other ARV agents
-- To view the remaining sections of this topic, please log in or purchase a subscription --
INDICATIONS
FDA
Tivicay: Treatment of HIV-1 infection in combination with other ARV agents in adults and children weighing ≥30 kg
Triumeq: Treatment of HIV-1 infection in adults and children weighing ≥40 kg
Juluca: Treatment of HIV-1 infection as a complete regimen for adult patients already virologically suppressed on stable ART for 6 months and no known resistance to dolutegravir or rilpivirine
NON-FDA APPROVED USES
Non-occupational post-exposure prophylaxis (nPEP) in combination with other ARV agents
There's more to see -- the rest of this topic is available only to subscribers.
